Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/28586789/ below:

The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population

Clinical Trial

Affiliations

• ¹ SWOG Statistical Center, Seattle, Washington.
• ² Fred Hutchinson Cancer Research Center, Seattle, Washington.
• ³ SWOG Group Chair's Office, Knight Cancer Institute, Oregon Health & Science University, Portland.

• PMID: 28586789
• PMCID: PMC5710507
• DOI: 10.1001/jamaoncol.2017.0762

Item in Clipboard

Clinical Trial

Joseph M Unger et al. JAMA Oncol. 2017.

• ¹ SWOG Statistical Center, Seattle, Washington.
• ² Fred Hutchinson Cancer Research Center, Seattle, Washington.
• ³ SWOG Group Chair's Office, Knight Cancer Institute, Oregon Health & Science University, Portland.

• PMID: 28586789
• PMCID: PMC5710507
• DOI: 10.1001/jamaoncol.2017.0762

Item in Clipboard

Importance: Recently, tremendous prominence has been given to the investigation of the effect of different research processes as part of the Cancer Moonshot. More than half a century ago, the National Cancer Institute (NCI) established a network of publicly funded cancer cooperative research groups to systematically evaluate new treatments for efficacy and safety.

Objective: To examine the extent to which positive NCI-sponsored cancer treatment trials have benefited patients with cancer in the US population.

Design, setting, and participants: This investigation used study data from SWOG, an NCI-sponsored network cooperative research group. All treatment trials during SWOG's 60-year history (1956-2016) were identified for which the new, experimental therapy provided a statistically significant improvement in overall survival. It was assumed that the new, proven treatments from these trials established new standards for cancer care in the treatment community. Twenty-three positive SWOG treatment trials were identified from a variety of different disease settings.

Main outcomes and measures: This study estimated population life-years gained from the 23 treatment trials through 2015 by mapping the effect of the new treatments onto the US cancer population using an area under the Kaplan-Meier survival curve approach that combined trial-specific hazard function and hazard ratio results, along with Surveillance, Epidemiology, and End Results program and life table data. Calculations were age adjusted. The US dollar return on investment was estimated as the ratio of the total investment by the NCI in the treatment trial program divided by the estimate of life-years gained.

Results: In total, 12 361 patients were enrolled to the 23 positive trials from 1965 to 2012. The study estimated that 3.34 million (95% confidence limit, 2.39-4.15 million) life-years were gained from these 23 trials through 2015. Estimates were greater than 2 million life-years gained under most model simulations. The US dollar return on investment was $125 per life-year gained.

Conclusions and relevance: SWOG treatment trials have had a substantial impact on population survival for patients with cancer over 60 years. The NCI's investment in its cancer cooperative group research program has provided exceptional value and benefit to the American public through its research programs generating positive cancer treatment trials.

Trial registration: clinicaltrials.gov Identifiers: NCT00004001, NCT00075764, and NCT00644228.

PubMed Disclaimer

Conflict of Interest Disclosures: None reported.

Shown are the estimated life-years gained…

Shown are the estimated life-years gained by SWOG trial through 2015.

Each color-coded area represents cumulative life-years…

Each color-coded area represents cumulative life-years for 1 of 23 studies.

• Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.

  Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ Jr, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Unger JM, et al. J Clin Oncol. 2023 Apr 10;41(11):2020-2028. doi: 10.1200/JCO.22.01826. Epub 2022 Dec 8. J Clin Oncol. 2023. PMID: 36480773 Free PMC article.

• The future of Cochrane Neonatal.

  Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834

• Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.

  Unger JM, Beauchemin M, Hershman DL. Unger JM, et al. Cancer. 2021 Dec 15;127(24):4574-4584. doi: 10.1002/cncr.33855. Epub 2021 Aug 5. Cancer. 2021. PMID: 34351619 Free PMC article.

• A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies.

  Deverka PA, Bangs R, Kreizenbeck K, Delaney DM, Hershman DL, Blanke CD, Ramsey SD. Deverka PA, et al. J Natl Cancer Inst. 2018 Jun 1;110(6):553-559. doi: 10.1093/jnci/djy064. J Natl Cancer Inst. 2018. PMID: 29684151 Free PMC article. Review.

• Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.

  Nghiem VT, Vaidya R, Lyman GH, Hershman DL, Ramsey SD, Unger JM. Nghiem VT, et al. Value Health. 2020 Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9. Value Health. 2020. PMID: 33248521 Free PMC article. Review.

• Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape.

  Oosting SF, Fehrmann RS, de Vries EGE. Oosting SF, et al. ESMO Open. 2017 Oct 9;2(4):e000272. doi: 10.1136/esmoopen-2017-000272. eCollection 2017. ESMO Open. 2017. PMID: 29226919 Free PMC article. No abstract available.

• Oncology clinical trials and insurance coverage: An update in a tenuous insurance landscape.

  Obeng-Gyasi S, Kircher SM, Lipking KP, Keele BJ, Benson AB, Wagner LI, Carlos RC. Obeng-Gyasi S, et al. Cancer. 2019 Oct 15;125(20):3488-3493. doi: 10.1002/cncr.32360. Epub 2019 Jun 28. Cancer. 2019. PMID: 31251394 Free PMC article.

• Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.

  Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM. Ho G, et al. Cancer. 2018 May 1;124(9):1938-1945. doi: 10.1002/cncr.31296. Epub 2018 Feb 16. Cancer. 2018. PMID: 29451695 Free PMC article.

• How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.

  Sehouli J, Boer J, Brand AH, Oza AM, O'Donnell J, Bennett K, Glaspool R, Lee CK, Ethier JL, Harter P, Seebacher-Shariat V, Chang TC, Cohen PA, van Gorp T, Chavez-Blanco A, Welch S, Hranovska H, O'Toole S, Lok CAR, Madariaga A, Rauh-Hain JA, Perez Fidalgo A, Tan D, Michels J, Pothuri B, Fujiwara N, Rosengarten O, Nishio H, Kim SI, Mukopadhyay A, Piovano E, Cecere SC, Kohn EC, Mukherjee U, Nasser S, Lindemann K, Croke J, Chen X, Geissler F, Bookman MA. Sehouli J, et al. Int J Gynecol Cancer. 2024 Nov 4;34(11):1677-1684. doi: 10.1136/ijgc-2024-005982. Int J Gynecol Cancer. 2024. PMID: 39496422 Free PMC article.

• Population, Clinical, and Scientific Impact of National Cancer Institute's National Clinical Trials Network Treatment Studies.

  Unger JM, LeBlanc M, George S, Wolmark N, Curran WJ Jr, O'Dwyer PJ, Schnall MD, Mannel RS, Mandrekar SJ, Gray RJ, Zhao F, Bah M, Vaidya R, Blanke CD. Unger JM, et al. J Clin Oncol. 2023 Apr 10;41(11):2020-2028. doi: 10.1200/JCO.22.01826. Epub 2022 Dec 8. J Clin Oncol. 2023. PMID: 36480773 Free PMC article.

1. 1. National Cancer Institute Cancer trends progress report: person-years of life lost. http://www.progressreport.cancer.gov/end/life_lost. Accessed March 29, 2017.
2. 1. Nass SJ, Moses HL, Mendelsohn J, eds; Institute of Medicine Committee on Cancer Clinical Trials and the NCI Cooperative Group Program. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: National Academies Press; 2010. - PubMed
3. 1. SWOG Cancer Research Fast facts. http://www.swog.org/Media/SWOG-Fast-Facts.pdf. Published 2014. Accessed March 29, 2017.
4. 1. National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report http://www.cancer.gov/brp. Published 2016. Accessed March 29, 2017.
5. 1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER data, 1973-2013. Released April 2016, based on the November 2015 submission. http://www.seer.cancer.gov. Accessed June 14, 2016.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3